Phase I
Shares of Moderna are down nearly 10% this morning despite the company posting positive interim results from an experimental seasonal flu vaccine.
Proof of concept for the Genetically Engineered Microbial Medicines (GEMM) platform came in a recent first-in-human, Phase I trial.
ADI-001 generated positive early responses from three of four evaluable participants, two of whom achieved complete responses while one had a partial response that researchers logged as “near complete.”
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
Parkinson’s disease has been immensely challenging for biotech companies. A high rate of late-stage attrition in trials has led to a lack of approved therapies for the disease.
One day after falsified information regarding its Phase I/II breast cancer data circulated online, Olema Pharmaceuticals released its topline data for a potential best-in-class complete estrogen receptor antagonist.
In October, Vertex Pharmaceuticals announced stunning results in a type 1 diabetes patient who had been dosed with the company’s experimental therapy.
Treatment for non-alcoholic steatohepatitis (NASH), a severe form of fatty liver disease, consists mainly of lifestyle modification – specifically dieting and weight loss.
Thanksgiving week was marked by numerous clinical trial announcements. Here’s a look.
Positive data from an ongoing Phase Ib study has impressed investors in Aptevo Therapeutics.
PRESS RELEASES